Contact Us
Drug Search Results
More Filters [+]

SYN-045

Alternative Names: SYN-045, SYN 045, SYN045
Latest Update: None
Latest Update Note: None

Product Description

SYN-045 is a highly selective PGI2 receptor agonist. Currently, in preclinical studies, SYN-045 shows high targeting selectivity, has obvious anti-pulmonary hypertension effects in animals, and its toxicity is low, which is conducive to long-term oral administration. (Sourced from: https://www.webull.com/news/10129086276207616)

Mechanisms of Action: PGI2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shijiazhuang No.4 Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SYN-045

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hypertension, Pulmonary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ChiCTR2400083835

N/A

Recruiting

Healthy Volunteers

2024-12-31

CTR20241522

P1

Unknown

Hypertension, Pulmonary

None

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions